Jazz Pharmaceuticals JAZZ Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's total current liabilities?
- Jazz Pharmaceuticals (JAZZ) reported total current liabilities of $2.25B in Q1 2026.
- How has Jazz Pharmaceuticals's total current liabilities changed year-over-year?
- Jazz Pharmaceuticals's total current liabilities increased by 83.8% year-over-year, from $1.22B to $2.25B.
- What is the long-term trend for Jazz Pharmaceuticals's total current liabilities?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's total current liabilities has grown at a 28.0% compound annual growth rate (CAGR), from $653.75M to $2.24B.
- What does total current liabilities mean?
- The total amount of debt and obligations due within one year.
- How do you interpret total current liabilities?
- A rising trend relative to current assets may signal liquidity strain, while a stable or declining trend suggests healthy working capital management.
- How does total current liabilities compare across companies?
- Used to calculate the Current Ratio; peers with similar business models should have comparable liquidity profiles.